Developments in the Management of Growth Hormone Deficiency: Clinical Utility of Somapacitan

References

• Christiansen JS, Backeljauw PF, Bidlingmaier M, et al. Growth Hormone Research Society perspective on the development of long-acting growth hormone preparations. Eur J Endocrinol. 2016;174(6):C1–C8. doi:10.1530/EJE-16-0111
   PubMed Web of Science ®Google Scholar
• Cramer JA, Benedict A, Muszbek N, Keskinaslan A, Khan ZM. The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review. Int J Clin Pract. 2008;62(1):76–87. doi:10.1111/j.1742-1241.2007.01630.x
   PubMed Web of Science ®Google Scholar
• Loftus J, Miller BS, Parzynski CS, et al. Association of daily growth hormone injection adherence and height among children with growth hormone deficiency. Endocr Pract. 2022;28(6):565–571. doi:10.1016/j.eprac.2022.02.013
   PubMed Web of Science ®Google Scholar
• Lass N, Reinehr T. Low treatment adherence in pubertal children treated with thyroxin or growth hormone. Horm Res Paediatr. 2015;84(4):240–247. doi:10.1159/000437305
   PubMed Web of Science ®Google Scholar
• Miller BS, Rotenstein D, Deeb LC, Germak J, Wisniewski T. Persistence with growth hormone therapy in pediatric patients. Am J Pharm Benefits. 2014;6(1):e9–e17.
   Google Scholar
• Loftus J, Wogen J, Oliveri D, et al. Persistence with daily growth hormone among children and adolescents with growth hormone deficiency in the UK. Front Endocrinol. 2022;13:1014743. doi:10.3389/fendo.2022.1014743
   PubMed Web of Science ®Google Scholar
• Kreitschmann-Andermahr I, Siegel S, Unger N, et al. Motivation for and adherence to growth hormone replacement therapy in adults with hypopituitarism: the patients’ perspective. Pituitary. 2020;23(5):479–487. doi:10.1007/s11102-020-01046-y
   PubMed Web of Science ®Google Scholar
• Danielson E, Melin-Johansson C, Modanloo M. Adherence to treatment in patients with chronic diseases: from alertness to persistence. Int J Community Based Nurs Midwifery. 2019;7(4):248–257. doi:10.30476/IJCBNM.2019.81303.0
   PubMedGoogle Scholar
• Food and Drug Administration. FDA approves weekly therapy for adult growth hormone deficiency. Available from: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-weekly-therapy-adult-growth-hormone-deficiency. Accessed March 24, 2023.
   Google Scholar
• European Medicines Agency. Sogroya European public assessment report (EPAR). Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/sogroya. Accessed March 24, 2023.
   Google Scholar
• Pharmaceutical and Medical Devices Agency. Report on investigation results. Available from: https://www.pmda.go.jp/files/000246397.pdf. Accessed 24, March 2023.
   Google Scholar
• GlobalNewswire. Novo Nordisk A/S: Sogroya® data show potential as once-weekly treatment in children living with growth hormone deficiency. Available from: https://www.globenewswire.com/news-release/2022/06/12/2460802/0/en/Novo-Nordisk-A-S-Sogroya-data-show-potential-as-once-weekly-treatment-in-children-living-with-growth-hormone-deficiency.html. Accessed March 24, 2023.
   Google Scholar
• Novo Nordisk. FDA approves once-weekly Sogroya® for the treatment of children living with growth hormone deficiency. Available from: https://www.novonordisk-us.com/content/nncorp/us/en_us/media/news-archive/news-details.html?id=166098. Accessed May 30, 2023.
   Google Scholar
• Novo Nordisk. Sogroya(R) somapacitan-beco injection 10 mg pen. Available from: https://www.novo-pi.com/sogroya.pdf. Accessed April 13, 2023.
   Google Scholar
• Miller BS, Yuen KCJ. Spotlight on lonapegsomatropin once-weekly injection and its potential in the treatment of growth hormone deficiency in pediatric patients. Drug Des Devel Ther. 2022;16:2055–2066. doi:10.2147/DDDT.S336285
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Ngenla(R) European public assessment report (EPAR). Available from: https://www.ema.europa.eu/en/documents/assessment-report/ngenla-epar-public-assessment-report_en.pdf. Accessed January 12, 2023.
   Google Scholar
• European Medicines Agency. Sogroya SmPC. Available from: https://www.ema.europa.eu/en/documents/product-information/sogroya-epar-product-information_en.pdf. Accessed August 25, 2023.
   Google Scholar
• European Medicines Agency. Lonapegsomatropin: SmPC. Available from: https://www.ema.europa.eu/en/documents/product-information/skytrofa-previously-lonapegsomatropin-ascendis-pharma-epar-product-information_en.pdf.Accessed January 12, 2023.
   Google Scholar
• Food and Drug Administration. Highlights of prescribing information: Skytrofa. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761177s001lbl.pdf. Accessed January 12, 2023.
   Google Scholar
• European Medicines Agency. Lonapegsomatropin(R) European public assessment report (EPAR). Available from: https://www.ema.europa.eu/en/documents/assessment-report/lonapegsomatropin-ascendis-pharma-epar-public-assessment-report_en.pdf.Accessed.Accessed January 12, 2023.
   Google Scholar
• Højby Rasmussen M, Janukonyté J, Klose M, et al. Reversible albumin-binding GH possesses a potential once-weekly treatment profile in adult growth hormone deficiency. J Clin Endocrinol Metab. 2016;101(3):988–998. doi:10.1210/jc.2015-1991
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. A trial to investigate long term efficacy and safety of lonapegsomatropin in adults with growth hormone deficiency: NCT05171855. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT05171855. Accessed January 12, 2023.
   Google Scholar
• ClinicalTrials.gov. A phase 3, multicenter study to evaluate The efficacy and safety of MOD-4023 in adults with growth hormone deficiency. Available from: https://clinicaltrials.gov/ct2/show/NCT01909479. Accessed May 30, 2023.
   Google Scholar
• Helleberg H, Bjelke M, Damholt BB, Pedersen PJ, Rasmussen MH. Absorption, metabolism and excretion of once-weekly somapacitan, a long-acting growth hormone derivative, after single subcutaneous dosing in human subjects. Eur J Pharm Sci. 2021;167:106030. doi:10.1016/j.ejps.2021.106030
   PubMed Web of Science ®Google Scholar
• Johansson E, Nielsen AD, Demuth H, et al. Identification of binding sites on human serum albumin for somapacitan, a long-acting growth hormone derivative. Biochemistry. 2020;59(14):1410–1419. doi:10.1021/acs.biochem.0c00019
   PubMed Web of Science ®Google Scholar
• Deacon CF. Potential of liraglutide in the treatment of patients with type 2 diabetes. Vasc Health Risk Manag. 2009;5(1):199–211. doi:10.2147/VHRM.S4039
   PubMedGoogle Scholar
• Havelund S, Plum A, Ribel U, et al. The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharm Res. 2004;21(8):1498–1504. doi:10.1023/B:PHAM.0000036926.54824.37
   PubMed Web of Science ®Google Scholar
• Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide. Front Endocrinol. 2019;10:155. doi:10.3389/fendo.2019.00155
   PubMed Web of Science ®Google Scholar
• Petersen M, Gandhi PS, Buchardt J, et al. Tissue distribution and receptor activation by somapacitan, a long acting growth hormone derivative. Int J Mol Sci. 2020;21(4):1181. doi:10.3390/ijms21041181
   PubMed Web of Science ®Google Scholar
• Bentz Damholt B, Dombernowsky SL, Dahl Bendtsen M, Bisgaard C, Højby Rasmussen M. Effect of kidney or hepatic impairment on the pharmacokinetics and pharmacodynamics of somapacitan: two open-label, parallel-group trials. Clin Pharmacokinet. 2021;60(8):1015–1027. doi:10.1007/s40262-021-00990-7
   PubMed Web of Science ®Google Scholar
• Johannsson G, Gordon MB, Højby Rasmussen M, et al. Once-weekly somapacitan is effective and well tolerated in adults with GH deficiency: a randomized phase 3 trial. J Clin Endocrinol Metab. 2020;105(4):e1358–e1376. doi:10.1210/clinem/dgaa049
   PubMed Web of Science ®Google Scholar
• Otsuka F, Takahashi Y, Tahara S, Ogawa Y, Højby Rasmussen M, Takano K. Similar safety and efficacy in previously treated adults with growth hormone deficiency randomized to once-weekly somapacitan or daily growth hormone. Clin Endocrinol. 2020;93(5):620–628. doi:10.1111/cen.14273
   PubMed Web of Science ®Google Scholar
• Højby Rasmussen M, Brændholt Olsen MW, Alifrangis L, Klim S, Suntum M. A reversible albumin-binding growth hormone derivative is well tolerated and possesses a potential once-weekly treatment profile. J Clin Endocrinol Metab. 2014;99(10):E1819–E1829. doi:10.1210/jc.2014-1702
   PubMed Web of Science ®Google Scholar
• Johannsson G, Feldt-Rasmussen U, Håkonsson IH, et al. Safety and convenience of once-weekly somapacitan in adult GH deficiency: a 26-week randomized, controlled trial. Eur J Endocrinol. 2018;178(5):491–499. doi:10.1530/EJE-17-1073
   PubMed Web of Science ®Google Scholar
• Takahashi Y, Biller BMK, Fukuoka H, et al. Weekly somapacitan had no adverse effects on glucose metabolism in adults with growth hormone deficiency. Pituitary. 2023;26(1):57–72. doi:10.1007/s11102-022-01283-3
   PubMed Web of Science ®Google Scholar
• Sävendahl L, Battelino T, Brod M, et al. Once-weekly somapacitan vs daily GH in children with GH deficiency: results from a randomized phase 2 trial. J Clin Endocrinol Metab. 2020;105(4):e1847–e1861. doi:10.1210/clinem/dgz310
   PubMed Web of Science ®Google Scholar
• Sävendahl L, Battelino T, Højby Rasmussen M, Brod M, Saenger P, Horikawa R. Effective GH replacement with once-weekly somapacitan vs daily GH in children with GHD: 3-year results from REAL 3. J Clin Endocrinol Metab. 2022;107(5):1357–1367. doi:10.1210/clinem/dgab928
   PubMed Web of Science ®Google Scholar
• Sävendahl L, Battelino T, Højby Rasmussen M, et al. Weekly somapacitan in GH deficiency: 4-year efficacy, safety and treatment/disease burden results from REAL 3. J Clin Endocrinol Metab. 2023;108:2569–2578. doi:10.1210/clinem/dgad183
   PubMed Web of Science ®Google Scholar
• Miller BS, Blair JC, Rasmussen MH, et al. Weekly somapacitan is effective and well tolerated in children with GH deficiency: the randomized phase 3 REAL4 trial. J Clin Endocrinol Metab. 2022;107(12):3378–3388. doi:10.1210/clinem/dgac513
   PubMed Web of Science ®Google Scholar
• Miller BS, Blair JC, Rasmussen MH, et al. Effective GH replacement with somapacitan in children with GHD: REAL4 2-year results and after switch from daily GH. J Clin Endocrinol Metab. 2023;108:3090–3099. doi:10.1210/clinem/dgad394
   PubMedGoogle Scholar
• ClinicalTrials.gov. A research study in Chinese children with a low level of hormone to grow. Treatment is somapacitan once a week compared to Norditropin® once a day. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT04970654. Accessed January 12, 2023.
   Google Scholar
• Battelino T, Rasmussen MH, De Schepper J, Zuckerman-Levin N, Gucev Z, Sävendahl L. Somapacitan, a once-weekly reversible albumin-binding GH derivative, in children with GH deficiency: a randomized dose-escalation trial. Clin Endocrinol. 2017;87(4):350–358. doi:10.1111/cen.13409
   PubMed Web of Science ®Google Scholar
• Deal CL, Steelman J, Vlachopapadopoulou E, et al. Efficacy and safety of weekly somatrogon vs daily somatropin in children with growth hormone deficiency: a phase 3 study. J Clin Endocrinol Metab. 2022;107(7):e2717–e2728. doi:10.1210/clinem/dgac220
   PubMed Web of Science ®Google Scholar
• Horikawa R, Tanaka T, Hasegawa Y, et al. Efficacy and safety of once-weekly somatrogon compared with once-daily somatropin (Genotropin®) in Japanese children with pediatric growth hormone deficiency: results from a randomized phase 3 study. Horm Res Paediatr. 2022;95(3):275–285. doi:10.1159/000524600
   PubMed Web of Science ®Google Scholar
• Thornton PS, Maniatis AK, Aghajanova E, et al. Weekly lonapegsomatropin in treatment-naïve children with growth hormone deficiency: the phase 3 heiGHt trial. J Clin Endocrinol Metab. 2021;106(11):3184–3195. doi:10.1210/clinem/dgab529
   PubMed Web of Science ®Google Scholar
• Bidlingmaier M, Schilbach K. The use of IGF-I to monitor long-acting growth hormone therapy-timing is an art…. J Clin Endocrinol Metab. 2021;106(5):e2367–e2369. doi:10.1210/clinem/dgab016
   PubMed Web of Science ®Google Scholar
• Kildemoes RJ, Hollensen C, Biller BMK, Johannsson G, Takahashi Y, Rasmussen MH. Dose-exposure-IGF-I response of once-weekly somapacitan in adults with GH deficiency. Eur J Endocrinol. 2022;187(1):27–38. doi:10.1530/EJE-21-1167
   PubMed Web of Science ®Google Scholar
• Juul RV, Rasmussen MH, Agersø H, Overgaard RV. Pharmacokinetics and pharmacodynamics of once-weekly somapacitan in children and adults: supporting dosing rationales with a model-based analysis of three Phase I trials. Clin Pharmacokinet. 2019;58(1):63–75. doi:10.1007/s40262-018-0662-5
   PubMed Web of Science ®Google Scholar
• Juul Kildemoes R, Højby Rasmussen M, Agersø H, Overgaard RV. Optimal monitoring of weekly IGF-I levels during growth hormone therapy with once-weekly somapacitan. J Clin Endocrinol Metab. 2021;106(2):567–576. doi:10.1210/clinem/dgaa775
   PubMed Web of Science ®Google Scholar
• Kildemoes RJ, Backeljauw PF, Højby M, et al. Model-based analysis of IGF-I response, dosing, and monitoring for once-weekly somapacitan in children with GH deficiency. J Endocr Soc. 2023;7(11):bvad115. doi:10.1210/jendso/bvad115
   PubMed Web of Science ®Google Scholar
• Maniatis AK, Carakushansky M, Galcheva S, et al. Treatment burden of weekly somatrogon vs daily somatropin in children with growth hormone deficiency: a randomized study. J Endocr Soc. 2022;6(10):bvac117. doi:10.1210/jendso/bvac117
   PubMed Web of Science ®Google Scholar
• Maniatis AK, Nadgir U, Saenger P, et al. Switching to weekly lonapegsomatropin from daily somatropin in children with growth hormone deficiency: the fliGHt trial. Horm Res Paediatr. 2022;95(3):233–243. doi:10.1159/000524003
   PubMed Web of Science ®Google Scholar
• Miller BS. What do we do now that the long-acting growth hormone is here? Front Endocrinol. 2022;13:980979. doi:10.3389/fendo.2022.980979
   PubMed Web of Science ®Google Scholar
• Miller BS, Velazquez E, Yuen KCJ. Long-acting growth hormone preparations - current status and future considerations. J Clin Endocrinol Metab. 2020;105(6):e2121–e2133. doi:10.1210/clinem/dgz149
   PubMed Web of Science ®Google Scholar
• Maniatis AK, Casella SJ, Nadgir UM, et al. Safety and efficacy of lonapegsomatropin in children with growth hormone deficiency: enliGHten trial 2-year results. J Clin Endocrinol Metab. 2022;107(7):e2680–e2689. doi:10.1210/clinem/dgac217
   PubMed Web of Science ®Google Scholar
• Miller B, Savendahl L, Hickman K, et al. A long-acting growth hormone module for paediatric growth hormone deficiency in the Global Registry For Novel Therapies In Rare Bone & Endocrine Conditions – The GloBE-Reg LAGH Study. Available from: https://www.karger.com/Article/Pdf/525606. Accessed April 13, 2023.
   Google Scholar
• McNamara M, Turner-Bowker D, Westhead H, et al. Factors driving patient preferences for growth hormone deficiency (GHD) injection regimen and injection device features: a discrete choice experiment. Patient Prefer Adherence. 2020;14:781–793. doi:10.2147/PPA.S239196
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Highlights of prescribing information for Skytrofa. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761177lbl.pdf. Accessed May 04, 2023.
   Google Scholar
• European Medicines Agency. Ngenla: SmPC. Available from: https://www.ema.europa.eu/en/documents/product-information/ngenla-epar-product-information_en.pdf. Accessed May 04, 2023.
   Google Scholar
• Rivolo S, Loftus J, Peter B, et al. Cost-effectiveness and cost-utility analysis of somatrogon once-weekly injectable vs. daily growth hormones for treating pediatric growth hormone deficiency. Poster EE27. Poster presented at: Annual Meeting of ISPOR Europe; 2022. Vienna, Austria.
   Google Scholar
• Mehl A, Goh A, Gupta S. Cost-effectiveness of once-daily somatropin from Sandoz versus once-weekly somatrogon for the treatment of growth hormone deficiency in children and adolescents. Poster EE589. Poster presented at: Annual Meeting of ISPOR Europe; 2022. Vienna, Austria.
   Google Scholar
• Patterson BC, Chen Y, Sklar CA, et al. Growth hormone exposure as a risk factor for the development of subsequent neoplasms of the central nervous system: a report from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab. 2014;99(6):2030–2037. doi:10.1210/jc.2013-4159
   PubMed Web of Science ®Google Scholar
• Darzy KH, Shalet SM. Pathophysiology of radiation-induced growth hormone deficiency: efficacy and safety of GH replacement. Growth Hormone IGF Res. 2006;16:30–40. doi:10.1016/j.ghir.2006.03.002
   Web of Science ®Google Scholar
• He M, Deng X, Wang X, et al. Association between recombinant growth hormone therapy and all-cause mortality and cancer risk in childhood: systematic review and meta-analysis. Front Pediatr. 2022;10:866295. doi:10.3389/fped.2022.866295
   PubMed Web of Science ®Google Scholar
• Jenkins PJ, Mukherjee A, Shalet SM. Does growth hormone cause cancer? Clin Endocrinol. 2006;64(2):115–121. doi:10.1111/j.1365-2265.2005.02404.x
   PubMed Web of Science ®Google Scholar
• Boguszewski MCS, Boguszewski CL, Chemaitilly W, et al. Safety of growth hormone replacement in survivors of cancer and intracranial and pituitary tumours: a consensus statement. Eur J Endocrinol. 2022;186(6):P35–P52. doi:10.1530/EJE-21-1186
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Investigating efficacy and safety of once-weekly NNC0195-0092 (somapacitan) treatment compared to daily growth hormone treatment (Norditropin® Flexpro®) in growth hormone treatment naïve pre-pubertal children with growth hormone deficiency. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT02616562?draw=2. Accessed April 13, 2023.
   Google Scholar